
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is expected to continue its growth trajectory, with a projected revenue of $350M-$360M in 2026 and a target of $250M in quarterly revenue by 2027. With a strong focus on expanding its product portfolio and targeted marketing efforts, the company is poised for success. The recent J-code approval for one of its key drugs is also expected to drive adoption and contribute to the company's growth. Overall, Harrow's strong financial performance and strategic initiatives make it a promising investment opportunity in the eyecare industry.
Bears say
Harrow is key product IHEEZO launch has not been going as well as initially expected. The revenue recognition shift for the drug may impact its near-term growth, and additional competition in the market from other cyclosporine agents may hinder its long-term success. Additionally, uncertainty around the strength and defense of Harrow's patents presents a potential risk for the company's future revenue streams and financial stability.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares